Optirtp Limited

At OptiRTP (Return to Play), we believe recovery should be personal, accessible, and grounded in science. Born from an act of compassion — a son’s search to ease his father’s pain — our journey has evolved into a decade of research, engineering, and clinical alignment focused on helping people support their body’s natural ability to recover and self-regulate. Our technology, Optimum Bio Sound Therapy (OBST), is a Class I, non-invasive, drug-free digital therapeutic, delivered through a secure in-home medical platform. OBST uses proprietary low-frequency acoustic modulation — a form of “bio-tuning” that engages the body’s innate systems for pain management, recovery, and wound healing. Registered with both Medsafe (NZ) and the U.S. FDA, OBST is 510(k)-exempt and legally cleared for commercial use within its indicated purposes. Over the past decade, we’ve delivered more than therapy hours to 1,100+ users, continuously refining the platform through real-world biofeedback and data-driven iteration. In 2026, OptiRTP will expand commercially into the United States, alongside a clinical validation initiative designed to further strengthen the evidence base and support future regulatory milestones. Expansion into Japan will follow in 2027, as we continue building the infrastructure and partnerships required for global scale. Our purpose remains simple yet ambitious: To bring affordable, evidence-based healthcare to the world — so that what began as help for one person can become hope for millions.